Septerna Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SEPN research report →
About the company
Septerna, Inc. , a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease.
- CEO
- Jeffrey T. Finer
- IPO
- 2024
- Employees
- 130
- HQ
- South San Francisco, CA, US
Price Chart
- Market Cap
- $1.53B
- P/E
- -41.98
- P/S
- 21.21
- P/B
- 4.02
- EV/EBITDA
- -28.47
- Div Yield
- 0.00%
- Gross Margin
- 99.42%
- Op Margin
- -77.07%
- Net Margin
- -49.88%
- ROE
- -9.44%
- ROIC
- -11.28%
- Revenue
- $45.95M · 4174.51%
- Net Income
- $-48,879,000 · 31.92%
- EPS
- $-1.10 · 43.01%
- Op Income
- $-80,797,000
- FCF YoY
- 257.63%
- 52W High
- $37.99
- 52W Low
- $10.62
- 50D MA
- $29.57
- 200D MA
- $25.70
- Beta
- 2.28
- Avg Volume
- 382.00K
Get TickerSpark's AI analysis on SEPN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Long Daniel D. | other | 3,333 |
| Jul 1, 26 | Long Daniel D. | sell | 2,100 |
| Jul 1, 26 | Long Daniel D. | sell | 1,233 |
| Jul 1, 26 | Long Daniel D. | other | 3,333 |
| Jun 26, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 15,000 |
| Jun 29, 26 | Shaikhly Samira | other | 2,178 |
| Jun 29, 26 | Shaikhly Samira | other | 2,178 |
| Jun 29, 26 | Shaikhly Samira | sell | 2,178 |
| Jun 26, 26 | Bassan Abraham | other | 15,000 |
| Jun 26, 26 | Sharp Shalini | other | 15,000 |
Our SEPN coverage
Recent articles, reports, and earnings notes.
No research on SEPN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SEPN report →Similar companies
Peers in the same neighborhood.